Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/07391102.2020.1837680

http://scihub22266oqcxt.onion/10.1080/07391102.2020.1837680
suck pdf from google scholar
33094680!7597227!33094680
unlimited free pdf from europmc33094680    free
PDF from PMC    free
html from PMC    free
PDF vom PMID33094680  :  Publisher

suck abstract from ncbi

pmid33094680
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease #MMPMID33094680
  • Mandour YM; Zlotos DP; Alaraby Salem M
  • J Biomol Struct Dyn 2020[Oct]; ä (ä): 1-12 PMID33094680show ga
  • Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global health emergency. Repurposing of approved pharmaceutical drugs for COVID-19 treatment represents an attractive approach to quickly identify promising drug candidates. SARS-CoV-2 main protease (M(pro)) is responsible for the maturation of viral functional proteins making it a key antiviral target. Based on the recently revealed crystal structures of SARS-CoV-2 M(pro), we herein describe a multi-stage virtual screening protocol including pharmacophore screening, molecular docking and protein-ligand interaction fingerprints (PLIF) post-docking filtration for efficient enrichment of potent SARS-CoV-2 M(pro) inhibitors. Potential hits, along with a cocrystallized control were further studied via molecular dynamics. A 150-ns production trajectory was followed by RMSD, free energy calculation, and H-bond analysis for each compound. The applied virtual screening protocol led to identification of five FDA-approved drugs with promising binding modes to key subsites of the substrate-binding pocket of SARS-CoV-2 M(pro). The identified compounds belong to different pharmaceutical classes, including several protease inhibitors, antineoplastic agents and a natural flavonoid. The drug candidates discovered in this study present a potential extension of the recently reported SARS-CoV-2 M(pro) inhibitors that have been identified using other virtual screening protocols and may be repurposed for COVID-19 treatment.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    1 ä.ä 2020